Hypertension and Angina Management

Introduction to Guidelines

The European Heart Journal recommends using intravenous agents such as nicardipine or clevidipine instead of immediate-release nifedipine for hypertensive emergencies, as supported by the American Heart Association 1, 2

The European Society of Cardiology recommends beta-blockers and/or calcium channel blockers (CCBs) as first-line treatment for most patients with chronic angina, with short-acting nitrates for immediate symptom relief, as also recommended by the American College of Cardiology 3, 4, 5
Short-acting nitrates are recommended for immediate relief of acute angina symptoms, and should be taken as needed in response to pain and prophylactically before engaging in activities that trigger angina, with a standard formulation of sublingual glyceryl trinitrate (nitroglycerin) 3, 6
The American College of Cardiology recommends first-line therapy with beta blockers, ACE inhibitors, or ARBs for hypertension with stable ischemic heart disease (SIHD), and adding dihydropyridine calcium channel blockers (DHPs) if blood pressure goal is not met or if angina persists 4, 5

Beta-blockers are recommended as first-line therapy for most patients with chronic coronary syndrome (CCS), particularly beneficial for patients with prior myocardial infarction, heart failure with reduced ejection fraction, hypertension, and tachyarrhythmias, as recommended by the European Society of Cardiology and the American College of Cardiology 3, 7
Common beta-blocker options include metoprolol, atenolol, bisoprolol, and carvedilol, with specific dosing recommendations, and caution should be exercised when using beta-blockers in patients with sick sinus syndrome, AV conduction disorders, severe bradycardia, or hypotension 3, 7

Calcium channel blockers are recommended as first-line alternative when beta-blockers are contraindicated or not tolerated, and should be used with care in heart failure with reduced ejection fraction, as recommended by the European Society of Cardiology and the American College of Cardiology 3, 8
Non-dihydropyridine CCBs (verapamil, diltiazem) should not be combined with ivabradine, and DHPs are preferred over non-dihydropyridine CCBs when combined with beta blockers to avoid excessive bradycardia or heart block, as recommended by the Circulation society 3, 9
Recommended DHP dosages are:
DHP Dosage
Felodipine 2.5-10 mg once daily
Isradipine 5-10 mg twice daily
Nicardipine SR 60-120 mg twice daily
Nifedipine LA 30-90 mg once daily
Nisoldipine 17-34 mg once daily

If symptoms are not adequately controlled with initial therapy, a combination of beta-blocker and dihydropyridine CCB should be considered first, and additional options for combination therapy include long-acting nitrates, ranolazine, nicorandil, and trimetazidine, with specific recommendations for each, as recommended by the American College of Cardiology 3, 6, 4, 5
The American College of Cardiology recommends adding thiazide diuretics and/or mineralocorticoid receptor antagonists if blood pressure is still not controlled 4

Nifedipine is contraindicated in patients with severe left ventricular dysfunction, pulmonary edema, heart failure with reduced ejection fraction, advanced aortic stenosis, and unstable angina or recent myocardial infarction, as recommended by the American College of Cardiology and the American Heart Association 7, 11, 2, 4, 12
Immediate-release nifedipine should not be used without concomitant beta-blockade due to increased risk of adverse cardiovascular events, as recommended by the American Heart Association 7, 13, 11
DHPs should be avoided in patients with heart failure with reduced ejection fraction (HFrEF), as recommended by the Circulation society 10

Common side effects of nifedipine IR include peripheral edema, flushing, headache, and dizziness, which should be monitored closely during treatment, as reported in the Circulation journal 14
Patients taking nifedipine should be monitored for signs of peripheral edema, and common adverse effects of nifedipine include hypotension, dizziness, flushing, nausea, constipation, and peripheral edema, which is more common with nifedipine than other calcium channel blockers 15, 7, 11

Aspirin should be given to all patients at a dose of 75-162 mg daily unless contraindicated, according to the American College of Cardiology 16, 6
Lipid management, blood pressure control, and smoking cessation are essential components of management, as recommended by the European Society of Cardiology 6
Combining ivabradine with verapamil or diltiazem is contraindicated, and using nitrates in patients taking phosphodiesterase inhibitors is also contraindicated, as recommended by the American College of Cardiology 3, 6
Nitrate tolerance develops with continuous use, and nitrate-free intervals should be ensured to avoid tolerance, as recommended by the American College of Cardiology 6